Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.18 USD | +3.22% | -2.32% | -28.06% |
09/05 | Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating | MT |
08/05 | Pharvaris N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.06% | 108.6Cr | |
+67.53% | 6.39TCr | |
-0.77% | 4.18TCr | |
+42.32% | 4.05TCr | |
-10.02% | 2.72TCr | |
+13.30% | 2.65TCr | |
-22.79% | 1.87TCr | |
+4.70% | 1.27TCr | |
+24.10% | 1.21TCr | |
+27.41% | 1.21TCr |
- Stock Market
- Equities
- PHVS Stock
- News Pharvaris N.V.
- Pharvaris Says US FDA Lifts Clinical Hold on IND Application for Hereditary Angioedema Treatment Candidate